X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
eFT508 (tomivosertib) is a potent and highly selective MNK inhibitor, small molecule drug candidate, which is being evaluated in combination with pembrolizumab for the treatment of non-small cell lung cancer.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
The net proceeds will focus on the development of eFT508 (tomivosertib), which is a small molecule inhibitor of MNK used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The net proceeds will be used to advance company's pipeline including, eFT508 (tomivosertib), an oral small molecule inhibitor of MNK1 and MNK2 and currently in Phase II for Head And Neck Cancer.
Lead Product(s): Tomivosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
eFT226 (zotatifin), a small molecule inhibitor of the RNA helicase eIF4A, is currently undergoing evaluation in Phase II clinical trials in combination with Fulvestrant for treating ER+ & HER2-negative Breast cancer.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of the RNA helicase eIF4A. It is being evaluated in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer.
Lead Product(s): Zotatifin,Fulvestrant,Abemaciclib
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
The collaboration aims to evaluate eFT508 (tomivosertib), an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E, in patients with relapsed/refractory Acute Myeloid Leukemia.
Lead Product(s): Tomivosertib
Therapeutic Area: Oncology Product Name: eFT508
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Northwestern University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2023
Details:
The collaboration will aims to evaluate eFT226 (zotatifin) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 11, 2023
Details:
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
eFT226 (Zotatifin) is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin,Fulvestrant
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
eFT226 (zotatifin) is potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS.
Lead Product(s): Zotatifin
Therapeutic Area: Infections and Infectious Diseases Product Name: eFT226
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
